ALBI Score: Calculation and Interpretation
The ALBI (Albumin-Bilirubin) score is calculated using the formula: (log₁₀ bilirubin [μmol/L] × 0.66) + (albumin [g/L] × -0.085), and provides an objective, evidence-based assessment of liver function that outperforms Child-Pugh scoring in patients with hepatocellular carcinoma and chronic liver disease. 1, 2
Calculation Method
The ALBI score requires only two objective laboratory values 2:
- Serum albumin (g/L)
- Total bilirubin (μmol/L)
Formula: ALBI score = (log₁₀ bilirubin [μmol/L] × 0.66) + (albumin [g/L] × -0.085) 2
Grade Classification
The ALBI score stratifies patients into three grades of liver dysfunction 2, 3:
- Grade 1 (low risk): ALBI score ≤ -2.60
- Grade 2 (intermediate risk): ALBI score > -2.60 to ≤ -1.39
- Grade 3 (high risk): ALBI score > -1.39
Clinical Interpretation and Prognostic Value
In Hepatocellular Carcinoma
The ALBI grade demonstrates superior discriminatory ability compared to Child-Pugh classification, particularly within Child-Pugh A patients where it identifies two distinct prognostic subgroups. 1, 2, 3
- The 2025 EASL guidelines recognize ALBI grade as an improved model for liver functional estimation in HCC patients 1
- ALBI grade independently predicts survival across all Barcelona Clinic Liver Cancer (BCLC) stages 3
- It correlates with post-hepatectomy liver failure, tumor relapse, and overall survival in patients undergoing curative treatments (resection, transplantation, ablation) 3
In Chronic Liver Disease Without HCC
For compensated cirrhosis, ALBI score accurately predicts 3-year decompensation risk with superior performance (time-dependent AUC 0.86) compared to MELD score (0.66), Child-Pugh score (0.65), and FIB-4 score (0.48). 4
The 3-year cumulative incidence of decompensation by ALBI grade 4:
- Low-risk (Grade 1): 3.1%
- Intermediate-risk (Grade 2): 22.6%
- High-risk (Grade 3): 50%
Patients in the high-risk ALBI group have a 23-fold increased odds of decompensation compared to low-risk patients 4.
Fibrosis Staging
ALBI score can differentiate advanced fibrosis stages in chronic hepatitis C, with an ALBI score of -2.125 serving as a cut-off to distinguish cirrhosis (stage 4) from earlier stages with 73.2% sensitivity and 87.1% specificity. 5
Key Advantages Over Traditional Scoring Systems
The ALBI grade eliminates subjective variables (ascites, encephalopathy) required in Child-Pugh scoring, providing a fully objective and reproducible assessment. 2, 3
- Detects subtle changes in liver dysfunction not captured by Child-Pugh classification 3
- Validated across multiple geographic regions and clinical settings 2
- Applicable to treatment selection and therapeutic sequencing 3
- Predicts outcomes beyond survival, including decompensation events and treatment toxicity 3, 4
Enhanced Predictive Models
Combining ALBI score with FIB-4 index (ALBI-FIB4 score) further improves prediction of post-hepatectomy liver failure (AUC 0.783) and postoperative mortality, outperforming individual scoring systems. 6
An ALBI-FIB4 cut-off of -1.82 stratifies patients into high-risk (39.1% PHLF incidence) versus low-risk (6.6% PHLF incidence) groups 6.
Clinical Pitfalls and Caveats
- While extensively validated in HCC populations, prospective validation in non-malignant liver disease is still evolving 7
- The score was originally derived for HCC patients; its application to compensated cirrhosis requires careful interpretation of risk thresholds 7
- Dynamic changes in ALBI score over time may provide additional prognostic information beyond single baseline measurements 7
- Small sample sizes in some validation studies for high-risk ALBI grades warrant cautious interpretation in specific clinical contexts 7